WO2008145721A3 - N-terminal modification of polypeptides for protection against degradation by aminopeptidases - Google Patents
N-terminal modification of polypeptides for protection against degradation by aminopeptidases Download PDFInfo
- Publication number
- WO2008145721A3 WO2008145721A3 PCT/EP2008/056673 EP2008056673W WO2008145721A3 WO 2008145721 A3 WO2008145721 A3 WO 2008145721A3 EP 2008056673 W EP2008056673 W EP 2008056673W WO 2008145721 A3 WO2008145721 A3 WO 2008145721A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polypeptides
- aminopeptidases
- protection against
- against degradation
- terminal modification
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/003—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by transforming the C-terminal amino acid to amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Abstract
N-terminally modified polypeptides comprising one or more N-terminal modifications consisting of an organic molecular substituent having a MW below 100 g per mol are ob- tained by the invention. Also compositions comprising such and the use thereof are com- prised by the invention.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07109440.3 | 2007-06-01 | ||
EP07109440 | 2007-06-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008145721A2 WO2008145721A2 (en) | 2008-12-04 |
WO2008145721A3 true WO2008145721A3 (en) | 2009-03-12 |
Family
ID=38473104
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2008/056673 WO2008145721A2 (en) | 2007-06-01 | 2008-05-30 | N-terminal modification of polypeptides for protection against degradation by aminopeptidases |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2008145721A2 (en) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009019027A (en) * | 2007-07-16 | 2009-01-29 | Hanmi Pharmaceutical Co Ltd | Insulin secretion peptide derivative in which amino acid of amino terminal is varied |
WO2011075430A1 (en) | 2009-12-14 | 2011-06-23 | University Of Massachusetts | Methods of inhibiting cataracts and presbyopia |
WO2011107494A1 (en) | 2010-03-03 | 2011-09-09 | Sanofi | Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof |
DE102010015123A1 (en) | 2010-04-16 | 2011-10-20 | Sanofi-Aventis Deutschland Gmbh | New benzylamidic diphenylazetidinone compounds, useful for treating lipid disorders, hyperlipidemia, atherosclerotic manifestations or insulin resistance, and for reducing serum cholesterol levels |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
WO2012049307A2 (en) | 2010-10-15 | 2012-04-19 | Novo Nordisk A/S | Novel n-terminally modified insulin derivatives |
CN103596584B (en) | 2011-06-15 | 2016-12-14 | 诺沃—诺迪斯克有限公司 | Polysubstituted insulin |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013093009A1 (en) | 2011-12-21 | 2013-06-27 | Novo Nordisk A/S | N -terminally modified insulin derivatives |
EP2968239B1 (en) * | 2013-03-14 | 2019-04-24 | The University of Massachusetts | Methods of inhibiting cataracts and presbyopia |
AR099569A1 (en) | 2014-02-28 | 2016-08-03 | Novo Nordisk As | INSULIN DERIVATIVES AND THE MEDICAL USES OF THESE |
CA2966765C (en) * | 2014-11-21 | 2020-04-14 | Merck Sharp & Dohme Corp. | Insulin receptor partial agonists |
MX2018005903A (en) | 2015-11-13 | 2019-04-04 | Univ Massachusetts | Bifunctional molecules containing peg for use in inhibiting cataracts and presbyopia. |
EP3517544A4 (en) | 2016-09-23 | 2020-06-03 | Hanmi Pharm. Co., Ltd. | Insulin analog having reduced binding force to insulin receptor, and use thereof |
JP2020511513A (en) | 2017-03-23 | 2020-04-16 | ハンミ ファーマシューティカル カンパニー リミテッド | Insulin analog conjugates having reduced binding to the insulin receptor and uses thereof |
MX2023008330A (en) | 2021-01-20 | 2024-01-18 | Viking Therapeutics Inc | Compositions and methods for the treatment of metabolic and liver disorders. |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003105677A2 (en) * | 2002-06-01 | 2003-12-24 | Praecis Pharmaceuticals, Inc. | Methods for treating viral diseases using modulators of amyloidogenic peptide aggregation |
-
2008
- 2008-05-30 WO PCT/EP2008/056673 patent/WO2008145721A2/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003105677A2 (en) * | 2002-06-01 | 2003-12-24 | Praecis Pharmaceuticals, Inc. | Methods for treating viral diseases using modulators of amyloidogenic peptide aggregation |
Non-Patent Citations (3)
Title |
---|
GLIEMANN J ET AL: "The biological activity and the binding affinity of modified insulins determined on isolated rat fat cells.", DIABETOLOGIA APR 1974, vol. 10, no. 2, April 1974 (1974-04-01), pages 105 - 113, XP002453103, ISSN: 0012-186X * |
HINDS KEN ET AL: "Synthesis and characterization of poly(ethylene glycol)-insulin conjugates", BIOCONJUGATE CHEMISTRY, ACS, WASHINGTON, DC, US, vol. 11, no. 2, 15 February 2000 (2000-02-15), pages 195 - 201, XP002391407, ISSN: 1043-1802 * |
UCHIO T ET AL: "Site-specific insulin conjugates with enhanced stability and extended action profile", ADVANCED DRUG DELIVERY REVIEWS, AMSTERDAM, NL, vol. 35, no. 2-3, 1999, pages 289 - 306, XP002363507, ISSN: 0169-409X * |
Also Published As
Publication number | Publication date |
---|---|
WO2008145721A2 (en) | 2008-12-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008145721A3 (en) | N-terminal modification of polypeptides for protection against degradation by aminopeptidases | |
WO2006099357A3 (en) | Polymerizable composition comprising low molecular weight organic component | |
PL2091987T3 (en) | Coating agents having high scratch resistance and weathering stability | |
WO2007106436A3 (en) | Photoactive compounds and compositions and uses thereof | |
MX2010003328A (en) | Cell-permeabilising peptides and polypeptides for microbial cells. | |
WO2007101698A3 (en) | Modified molecules which promote hematopoiesis | |
WO2006079076A3 (en) | Yersinia spp. polypeptides and methods of use | |
EP2548925A3 (en) | Poly (block-phosphonato-ester) and poly (block-phosphonato-carbonate) | |
WO2007023293A3 (en) | Luminescent material compositions and structures incorporating the same | |
EP1991688A4 (en) | Biodegradable compositions comprising renewably-based, biodegradable 1.3-propanediol | |
MX2009009900A (en) | Dendritic polyurethane coating. | |
WO2009149200A3 (en) | Compositions and methods comprising variant microbial proteases | |
WO2008014008A3 (en) | Compositions and methods for modulating angiogenesis | |
WO2006105387A8 (en) | Oleds utilizing direct injection to the triplet state | |
WO2009058564A3 (en) | Immunosuppressive polypeptides and nucleic acids | |
WO2008057697A3 (en) | Cross-linked polymer particles | |
WO2006103277A3 (en) | 2 , 4 , 5-substituted piperidines as renin inhibitors | |
WO2009123969A3 (en) | Deoxybenzoin-derived anti-flammable polymers | |
WO2006060189A3 (en) | Curable silicone compositions incorporating a fluorescent detection system | |
WO2006088803A3 (en) | Polypeptides from staphylococcus aureus and methods of use | |
WO2007079103A3 (en) | Compositions comprising novel compounds and electronic devices made with such compositions | |
WO2008104979A3 (en) | Nuclear targeting sequences | |
WO2008118567A3 (en) | Polythioether amine resins and compositions comprising same | |
WO2008078189A3 (en) | Factor vii and viia compositions | |
WO2007100574A3 (en) | Biodegradable phosphoester polyamines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08760263 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08760263 Country of ref document: EP Kind code of ref document: A2 |